Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Quadrature Capital Ltd

Quadrature Capital Ltd raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2,492.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,920 shares of the biopharmaceutical company’s stock after purchasing an additional 47,033 shares during the quarter. Quadrature Capital Ltd’s holdings in Alnylam Pharmaceuticals were worth $22,299,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ALNY. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $662,837,000. Arrowstreet Capital Limited Partnership increased its holdings in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after buying an additional 1,185,909 shares during the period. Holocene Advisors LP acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $194,616,000. Orbis Allan Gray Ltd raised its position in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $162,577,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 53,923 shares of company stock worth $18,072,087 over the last three months. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ ALNY opened at $317.23 on Friday. The firm has a market cap of $42.07 billion, a price-to-earnings ratio of 185.51 and a beta of 0.36. The company’s 50-day simple moving average is $346.09 and its 200-day simple moving average is $410.94. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the company earned ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target on the stock. Barclays began coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price on the stock. Wells Fargo & Company decreased their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Finally, Needham & Company LLC decreased their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.